%0 Journal Article
%A Lopez-Cortes, Luis F
%A Trujillo-Rodriguez, Maria
%A Baez-Palomo, Alicia
%A Benmarzouk-Hidalgo, Omar J
%A Dominguez-Molina, Beatriz
%A Milanes-Guisado, Yusnelkis
%A Espinosa, Nuria
%A Viciana, Pompeyo
%A Gutierrez-Valencia, Alicia
%T Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients.
%D 2018
%U http://hdl.handle.net/10668/12696
%X There are contradictory data about the influence that hepatitis C virus (HCV) has on immune activation and inflammation in patients coinfected with human immunodeficiency virus (HIV) and HCV. HIV/HCV-coinfected patients receiving antiretroviral treatment who achieved a sustained virological response with interferon-free regimens were consecutively enrolled in a prospective study. The following factors were assessed before, immediately after the end of, and 1 month after the end of therapy: expression of HLA-DR/CD38, PD-1, and CD57 on CD4+ and CD8+ T-cells; measurement of the total HIV DNA load in peripheral blood mononuclear cells; and determination of plasma levels of soluble CD14 (sCD14), lipopolysaccharide (LPS), 16S ribosomal DNA (rDNA), interleukin 6 (IL-6), D-dimers, and high-sensitivity C-reactive protein (hsCRP). Ninety-seven patients were consecutively included. At the end of therapy and 1 month later, there were significant reductions in the expression of HLA-DR and CD38 in CD4+ and CD8+ T cells, as well as levels of proviral HIV DNA, sCD14, LPS, 16S rDNA, and D-dimer (P  HCV eradication in HIV/HCV-coinfected patients results in significant decreases in levels of immune activation markers, proviral HIV DNA load, microbial translocation markers, and D-dimers. These findings support the use of HCV treatment for all HIV/HCV-coinfected patients, even those with low-grade fibrosis.
%K Bacterial Translocation
%K Antiviral Agents
%K HIV
%K Humans
%K Prospective Studies
%K Sustained Virologic Response
%K Treatment Outcome
%K Viral Load
%~